Aino Health (AINO.ST) Stock Analysis & AI Equity Report

Medical - Healthcare Information Services SEK Explore free reports

Aino Health (AINO.ST) overview

Aino Health (AINO.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Aino Health reported revenue of SEK 26.1m and operating profit of SEK -5.2m; the year-end share price was 0.17 SEK and market capitalisation was SEK 35.0m. Aino Health is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Aino Health's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK -6.4mFY 2025
Share price0.17 SEKFY 2025 year end
RevenueSEK 26.1mFY 2025
Operating profitSEK -5.2mFY 2025
Net earningsSEK -6.1mFY 2025
Market capitalisationSEK 35.0mFY 2025 year end

Figures updated on 2026-05-14. Data will be refreshed during report generation.

About Aino Health

Aino Health AB provides SaaS solutions and related services for corporate health management. Its platform helps employers manage work ability, track sickness absence, identify underlying causes of employee health issues, and support proactive interventions. The company serves public and private organizations, with revenue driven by software subscriptions, implementation, and customer support services.

Generate the Aino Health report

Aino Health is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Aino Health and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.